Browse the evidence

Treatment duration had minimal influence on primary outcomes.

Practitioners may not need to adjust treatment duration based on infection risk concerns.

The psychiatric side effects resolved with medication cessation.

Discontinuation of GLP-1 RAs may alleviate associated psychiatric symptoms.

Metabolomic subtypes have shown potential in guiding treatment selection for obesity.

Practitioners can consider metabolomic profiles to tailor obesity treatments.

Prolonged and unreasonable use of GLP-1 agonists may lead to undesirable effects.

Healthcare providers should monitor patients for potential adverse effects when using GLP-1 agonists long-term.

Integrating pharmacological, minimally invasive, and genetic strategies may enhance long-term weight management and metabolic outcomes.

Combining different treatment modalities may lead to better results for patients with obesity.

Obesity is a leading cause of morbidity and mortality with health consequences that crosscut most medical specialties.

Healthcare providers should recognize the widespread impact of obesity on health.

There are many impediments to comprehensive obesity care despite the emergence of effective therapies.

Clinicians should be aware of and address barriers to effective obesity treatment.

Current pharmacological treatments aim to restore energy balance by targeting disrupted pathways.

Practitioners should be aware of pharmacological options that target energy balance in obesity management.

Patient factors potentially contributing to increased aspiration risks included a higher body mass index, type 2 diabetes mellitus, gastro-oesophageal reflux disease, emergency case, and time from GLP-1 agonist cessation.

Understanding these risk factors can help clinicians better assess patients on GLP-1 agonists before surgery.

Resistance training tempo has minimal overall effect on muscle hypertrophy.

Practitioners may consider that varying resistance training tempo may not significantly impact muscle growth.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.

Internet search responses were more heterogeneous and often commercially biased.

Practitioners should critically evaluate internet sources for GLP1RA information due to potential bias.

Meta-regression showed no significant effect modification by age, body mass index, HbA1c, follow-up duration, or sodium-glucose co-transporter 2 inhibitors use.

The effectiveness of semaglutide is consistent regardless of these common patient characteristics.

Over half (60%) of participants with a BMI indicating obesity had no clinical diagnosis of obesity in their EHRs.

Clinicians should be aware that a significant number of patients with obesity may not be diagnosed, potentially leading to untreated health issues.

Men, and particularly NH-Asian men, may be at heightened risk of underdiagnosis of obesity.

Awareness of potential underdiagnosis in specific male populations can improve obesity management strategies.

NHB participants reported higher perceived discrimination, sleep disturbance, and perceived stress than H and NHW participants at all time points.

Addressing psychosocial factors is crucial for improving surgical outcomes in NHB patients.

There may be a potential causal relationship between tirzepatide and vitreous hemorrhage in nondiabetic patients.

Caution is advised when prescribing tirzepatide, especially in nondiabetic patients.

Emerging clinical trials support the potential of GLP-1 receptor agonists in reversing cancer risk.

Practitioners should stay updated on clinical trial results regarding GLP-1 agonists and cancer risk.

Dietary supplements are generally safe, but their regulation is less stringent than for medicines.

Practitioners should ensure patients are aware of the regulatory status of dietary supplements.